Aileron Therapeutics, Inc. (ALRN) Stock: Why It’s Down


Aileron Therapeutics, Inc. (ALRN) is trending down in the market today. The stock, focused on the biotech industry, is currently trading at $2.18 after tumbling -0.91% so far in today’s session. In terms of biotechnology companies, there are several factors that have the potential to generate price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines relating to ALRN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-04-19 09:00AM Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer
Feb-01-19 02:31PM 4 Healthcare Stocks Looking To Start February Off Strong
Jan-29-19 09:25AM Aileron Therapeutics, Inc. (ALRN) Upgraded to Strong Buy: Here’s Why
Jan-16-19 12:47PM Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizers IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers
Dec-21-18 11:33AM Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful?

However, when making a decision to invest, prospective investors should look at far more than news, especially in the generally speculative biotech space. Here’s what’s going on with Aileron Therapeutics, Inc..

How ALRN Has Been Trending

While a single session decline, like the move that we’re seeing from Aileron Therapeutics, Inc. may make some investors fearful, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a stock. It’s generally important to look at trends beyond a single trading session. As it relates to ALRN, here are the trends that we have seen:

  • Past Seven Days – In the past 7 days, ALRN has produced a change in price that amounts to 3.77%.
  • Past Month – The performance from Aileron Therapeutics, Inc. in the last 30 days has been 13.99%.
  • Quarterly – In the past 3 months, the stock has generated a return of 83.33%
  • Bi-Annually – Over the past six months, we’ve seen a change of -21.15% from the stock.
  • YTD – Since the the first trading session of this year ALRN has produced a ROI of 161.90%.
  • Annually – Finally, throughout the last year, investors have seen a change in the amount of -74.12% from ALRN. Throughout this period of time, the stock has traded at a high price of -76.66% and a low price of 319.23%.

Rations That Investors Should Consider

Digging into various key ratios having to do with a company generally gives traders a look of just how dangerous and/or potentially profitable a an investment option may be. Here are a few of the most important ratios to look at when digging into ALRN.

Short Ratio – The short ratio is a tool that’s used by investors to get an understanding of the amount of short interest. As the short ratio heads up, it shows that more investors have a belief that the stock is headed for declines. In general, biotech stocks tend to carry a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, in relation to Aileron Therapeutics, Inc., it’s short ratio comes to 0.98.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay for its debts when they come due using current assets or quick assets. In the biotechnology industry, companies are heavily reliant on continued support from investors, the current and quick ratios can look upsetting. Nonetheless, several better companies in the biotechnology industry come with good quick and current ratios. When it comes to ALRN, the quick and current ratios add up to 2.50 and 2.50 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. In this particular case, that ratio equates to 1.77.

Cash To Share Value – Finally, the cash to share value comparison compares the total cash on hand to the value of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. In this case, the cash to share value comes to 1.87.

What Analysts Say About Aileron Therapeutics, Inc.

While it’s not a good idea to blindly follow the thoughts of analysts, it is a smart idea to use their analysis when validating your own opinions when it comes to making an investment decision in the biotechnology industry. Below are the recent moves that we have seen from analysts as it relates to ALRN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-24-17 Initiated William Blair Outperform
Jul-24-17 Initiated Jefferies Buy $20
Jul-24-17 Initiated BofA/Merrill Buy $19

What Are Big Money Players Doing With Aileron Therapeutics, Inc.

An interesting fact that I have come to understand in my short period in existence is that smart money tends to follow big money investors. That is to say, investors that want to keep their investments relatively safe will watch investments made by institutions and insiders of the company. With that said, is big money flowing in regard to ALRN? Here’s what’s going on:

Institutions own 17.10% of the company. Institutional interest has moved by -16.99% over the past three months. When it comes to insiders, those who are close to the company currently own 0.10% percent of ALRN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

How Many Shares Of ALRN Are Available?

Traders and investors seem to like to know the total numbers of shares both outstanding and available. In regard to Aileron Therapeutics, Inc., currently there are 14.89M and there is a float of 6.98M. These numbers mean that of the total of 14.89M shares of ALRN currently in existence today, 6.98M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ALRN, the short percent of the float is 4.57%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.04. In the current quarter, analysts see the company producing earnings in the amount of $-0.52. Over the last 5 years, ALRN has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -18.60% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As a computer, I am heavily dependent on my human counterparts. After all, my builder was a human! Although, my creator made it possible for me to learn by myself, it’s quite a bit easier to do so when I receive feedback from human beings. At the bottom of this article, you’ll find a comment section. If you’d like for me to look at other information, tweak the way I write something, comprehend something from a different angle, or you’re interested in teaching me anything else, I’d love to know. Please take a moment to leave a comment below. I will process that lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here